세계의 만성 신장병 치료 시장

Global Chronic Kidney Disease Treatment Market to Reach US$17.2 Billion by 2030

The global market for Chronic Kidney Disease Treatment estimated at US$14.5 Billion in the year 2024, is expected to reach US$17.2 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Drugs, one of the segments analyzed in the report, is expected to record a 2.1% CAGR and reach US$10.9 Billion by the end of the analysis period. Growth in the Dialysis segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.0 Billion While China is Forecast to Grow at 5.4% CAGR

The Chronic Kidney Disease Treatment market in the U.S. is estimated at US$4.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Chronic Kidney Disease Treatment Market - Key Trends & Drivers Summarized

Why Is Chronic Kidney Disease Emerging as a High-Priority Global Health Burden?

Chronic Kidney Disease (CKD) is becoming an increasingly urgent public health concern, affecting over 850 million individuals worldwide and ranking among the top causes of mortality and disability-adjusted life years. The disease’s strong association with diabetes, hypertension, and cardiovascular disorders-coupled with rising aging populations-continues to drive its global prevalence. As early-stage CKD often remains asymptomatic, late diagnosis and progression to end-stage renal disease (ESRD) impose substantial clinical and economic burdens on healthcare systems, requiring long-term dialysis or organ transplantation.

Governments and health agencies are prioritizing CKD within noncommunicable disease (NCD) strategies due to its chronic trajectory, high treatment costs, and impact on workforce productivity. The shift toward preventive nephrology and early intervention is reinforcing demand for treatment modalities that delay disease progression, manage comorbidities, and reduce complications such as anemia, hyperphosphatemia, and mineral bone disorders. Public awareness campaigns and screening programs are also expanding, particularly in high-risk populations, to promote earlier diagnosis and engagement with treatment pathways.

How Are Pharmacological Advancements and Multi-Target Therapies Shaping CKD Treatment Approaches?

Pharmacological innovation is reshaping the CKD treatment paradigm, with a strong pipeline of novel agents that target disease-modifying pathways rather than solely managing symptoms. Sodium-glucose co-transporter-2 (SGLT2) inhibitors have gained prominence not only for their glycemic control but also for their renal-protective and cardiovascular benefits in both diabetic and non-diabetic CKD populations. These agents, along with nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) and endothelin receptor antagonists, are broadening therapeutic options beyond traditional ACE inhibitors and ARBs.

Combination therapies are increasingly being deployed to address the multifactorial nature of CKD progression, including inflammation, oxidative stress, and proteinuria. Meanwhile, the development of next-generation anemia treatments-such as hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs)-is enhancing outcomes for CKD-related anemia without the risks associated with erythropoiesis-stimulating agents. This multi-target approach is advancing CKD care toward more personalized and disease-specific regimens that emphasize renal function preservation and long-term risk reduction.

Which Delivery Models and Technologies Are Supporting Access and Continuity of CKD Care?

As healthcare systems prioritize early-stage CKD management, integrated care delivery models involving primary care, nephrology, nutrition, and behavioral health are gaining traction. These multidisciplinary programs aim to slow disease progression and optimize management of cardiovascular comorbidities through coordinated, protocol-driven interventions. Dialysis centers are also evolving to offer home-based peritoneal dialysis and hemodialysis options, supporting patient autonomy and reducing the logistical burden on facility-based care infrastructure.

Digital health tools-such as remote monitoring platforms, electronic health records with predictive analytics, and tele-nephrology-are improving continuity of care across geographies. These technologies enable early detection of functional decline, real-time medication adherence monitoring, and timely therapeutic adjustments. In resource-limited settings, mobile health (mHealth) apps and portable diagnostic devices are extending access to nephrology care and education, especially in rural and underserved populations where nephrologist shortages are acute.

How Are Payers and Policymakers Addressing the High Economic Burden of CKD Treatment?

CKD imposes one of the highest per-patient healthcare costs globally, particularly in its late stages where dialysis and transplantation dominate expenditures. As ESRD rates climb, public and private payers are reevaluating reimbursement frameworks to incentivize early intervention, promote cost-effective therapies, and delay dialysis initiation. Bundled payment models and value-based care contracts are being piloted to align provider incentives with patient outcomes in CKD management.

Policy measures are also expanding access to essential medicines, including the inclusion of newer agents in national formularies and reimbursement schemes. In some regions, governments are investing in CKD registries, risk stratification tools, and quality metrics to improve care oversight and resource allocation. Cross-sector collaboration with patient advocacy groups and pharmaceutical manufacturers is supporting medication affordability programs and public education initiatives-aimed at shifting CKD from a silent epidemic to a proactively managed chronic disease.

Can the Chronic Kidney Disease Treatment Market Drive Outcome-Centric Innovation While Addressing Global Disparities?

The path forward for CKD treatment lies in balancing innovation with equity-ensuring that novel therapies, diagnostic tools, and multidisciplinary care frameworks reach patients across all economic strata and healthcare systems. As treatment protocols become more sophisticated and data-driven, healthcare stakeholders must address persistent gaps in access, especially in low- and middle-income countries where diagnosis rates remain low and renal replacement therapies are unaffordable for most.

Achieving sustainable impact will require investment in workforce training, digital infrastructure, public health surveillance, and policy reform. As clinical evidence grows for renal-protective therapies and holistic disease management models, the central question emerges: Can the global CKD treatment market scale equitable, outcome-oriented care fast enough to mitigate long-term human and financial costs-while adapting to emerging science, demographic shifts, and system-level pressures?

SCOPE OF STUDY:

The report analyzes the Chronic Kidney Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Drug Type, Dialysis); End-Use (Hospitals & Clinics, Dialysis Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• AbbVie Inc.
• Akebia Therapeutics, Inc.
• Allena Pharmaceuticals
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim GmbH
• Cincor Pharma, Inc.
• DiaMedica Therapeutics Inc.
• Eli Lilly and Company
• Fresenius Medical Care AG & Co. KGaA
• GlaxoSmithKline plc
• Kibow Biotech, Inc.
• Lexicon Pharmaceuticals, Inc.
• Monogram Health
• Novo Nordisk A/S
• ProKidney Corp.
• Reata Pharmaceuticals, Inc.
• Sanofi S.A.
• Strive Health

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Chronic Kidney Disease Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Hypertension and Diabetes Drives Growth in CKD Treatment Market
  • Early-Stage CKD Management Gains Attention With Launch of SGLT2 Inhibitors and New Renoprotective Therapies
  • Expansion of Dialysis Infrastructure and Home Hemodialysis Technologies Improves Access to Late-Stage Care
  • Kidney Transplant Program Growth Strengthens Demand for Immunosuppressive and Supportive Therapies
  • Public Health Initiatives Focus on Early Detection and Risk Factor Control in At-Risk Populations
  • Multimodal Treatment Approaches Combine Lifestyle, Pharmacologic, and Digital Interventions
  • Renal Anemia and Mineral Bone Disorder Management Evolve With New Drug Classes and Formulations
  • Biopharma R&D Pipelines Focus on Anti-Inflammatory and Anti-Fibrotic Therapies for CKD
  • Clinical Decision Support Tools and Predictive Algorithms Enhance Progression Monitoring
  • Value-Based Kidney Care Contracts Encourage Outcomes-Driven Innovation in Treatment Delivery
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Chronic Kidney Disease Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Chronic Kidney Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Chronic Kidney Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Dialysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Dialysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Dialysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Dialysis Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Dialysis Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Dialysis Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 20: USA Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 21: USA Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: USA 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 23: USA Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: USA 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Canada Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: Canada 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: Canada 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 32: Japan Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Japan Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: Japan 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: Japan 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 38: China Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: China Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: China 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 41: China Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: China 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 44: Europe Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: Europe Historic Review for Chronic Kidney Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Europe 15-Year Perspective for Chronic Kidney Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Europe 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Europe 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 53: France Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: France Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: France 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 56: France Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: France 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 59: Germany Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Germany Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Germany 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Germany 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 65: Italy Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Italy Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Italy 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Italy 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 71: UK Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: UK Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: UK 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 74: UK Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: UK 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 77: Spain Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Spain Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Spain 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 80: Spain Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Spain Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Spain 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 83: Russia Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Russia Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Russia 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 86: Russia Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Russia Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Russia 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Rest of Europe Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Rest of Europe 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Rest of Europe 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 96: Asia-Pacific Historic Review for Chronic Kidney Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Asia-Pacific 15-Year Perspective for Chronic Kidney Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Asia-Pacific 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Asia-Pacific 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 104: Australia Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Australia Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Australia 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 107: Australia Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Australia Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Australia 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 110: India Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: India Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: India 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 113: India Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: India Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: India 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 116: South Korea Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: South Korea Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: South Korea 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 119: South Korea Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: South Korea Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: South Korea 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Rest of Asia-Pacific Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Rest of Asia-Pacific Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 128: Latin America Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 129: Latin America Historic Review for Chronic Kidney Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Latin America 15-Year Perspective for Chronic Kidney Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 131: Latin America Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Latin America Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Latin America 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Latin America 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 137: Argentina Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Argentina Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Argentina 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 140: Argentina Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Argentina Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Argentina 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 143: Brazil Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Brazil Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Brazil 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 146: Brazil Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Brazil Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Brazil 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 149: Mexico Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Mexico Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Mexico 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 152: Mexico Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Mexico Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Mexico 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Latin America Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Latin America 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Latin America Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Latin America 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 161: Middle East Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 162: Middle East Historic Review for Chronic Kidney Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Middle East 15-Year Perspective for Chronic Kidney Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 164: Middle East Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Middle East Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Middle East 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Middle East 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 170: Iran Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Iran Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Iran 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 173: Iran Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Iran Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Iran 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 176: Israel Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Israel Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Israel 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 179: Israel Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Israel Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Israel 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Saudi Arabia Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Saudi Arabia 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Saudi Arabia Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Saudi Arabia 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 188: UAE Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: UAE Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: UAE 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 191: UAE Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: UAE Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: UAE 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Middle East Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Middle East 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Middle East Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Middle East 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Chronic Kidney Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 200: Africa Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Africa Historic Review for Chronic Kidney Disease Treatment by Treatment Type - Drug Type and Dialysis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Africa 15-Year Perspective for Chronic Kidney Disease Treatment by Treatment Type - Percentage Breakdown of Value Sales for Drug Type and Dialysis for the Years 2015, 2025 & 2030
  • TABLE 203: Africa Recent Past, Current & Future Analysis for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Africa Historic Review for Chronic Kidney Disease Treatment by End-Use - Hospitals & Clinics, Dialysis Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Africa 15-Year Perspective for Chronic Kidney Disease Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Dialysis Centers and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION